Tokai gets funding to expand Phase II trial of galeterone in CRPC

Posted on May 16, 2013 by Sitemaster

In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

AUA also issues new guidance on treatment of patients with CRPC

Posted on May 6, 2013 by Sitemaster

Earlier today, the American Urological Association issued new guidance to its members on the management of patients with non-metastatic and metastatic castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 1 Comment »

Statins in clinical trials for advanced forms of prostate cancer

Posted on April 10, 2013 by Sitemaster

An editorial  by Freeman and Solomon (“Statin drugs and prostate cancer: time to consider proactive strategies in patients“) in the April issue of the Journal of Urology has proposed the idea of combining abiraterone acetate with a statin as a method to treat men with castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | Leave a Comment »

Recent lecture on the management of castration-resistant prostate cancer

Posted on April 10, 2013 by Sitemaster

The UroToday web site has just posted a detailed report on a presentation by Stephen Freedland, MD, of Duke University, given at the South East Section meeting of the American Urological Association in Williamsburg, VA, last month. This report will likely be of interest to patients with progressive forms of prostate cancer and many support group leaders. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , | 5 Comments »

Could EZH2 be critical to castration resistance?

Posted on December 17, 2012 by Sitemaster

According to an article published in Science on Friday last week, activation of an epigenetic regulator known as EZH2 (“enhancer of zeste homolog 2″) may be critical to the onset and progression of castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer | Tagged: , , , | Leave a Comment »

Tokai enrolls first patient into Phase II trial of galeterone in CRPC

Posted on December 13, 2012 by Sitemaster

According to a media release issued earlier today by Tokai Pharmaceuticals, the company has started treating men with castration-resistant prostate cancer (CRPC) in the Phase II ARMOR2 trial of galeterone (TOK-001). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer | Tagged: , , | Leave a Comment »

Effects of ketoconazole, abiraterone, and chemotherapy in men with CRPC

Posted on May 28, 2012 by Sitemaster

Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 1 Comment »

Managing advanced prostate cancer: what’s going to be presented at ASCO

Posted on May 27, 2012 by Sitemaster

So there are going to be > 180 papers specific to the management of prostate cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO) starting in Chicago next weekend. Some will be trivial; several will be “interesting”; a very few will be important. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

FDA rejects expanded indication for denosumab, as expected

Posted on April 27, 2012 by Sitemaster

According to a Reuters report issued late last night, the U.S. Food and Drug Administration (FDA) has rejected an application by Amgen to market denosumab (Xgeva®) as a treatment to delay the onset of bone metastases in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Management, Treatment | Tagged: , , , | 1 Comment »

SU2C and PCF fund $10 million research study into why / how new drugs work in mCRPC

Posted on April 2, 2012 by Sitemaster

Researchers at a consortium of seven major cancer centers have been awarded a $10 million, 3-year grant to continue explorations into the individualization of treatment for men with advanced and metastatic forms of prostate cancer. The grant is funded in a collaboration between Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

New options after standard hormone therapy has failed

Posted on October 1, 2011 by Sitemaster

We apparently managed to overlook a series of three review and commentary articles published in Oncology in May this year that dealt with the evolving options that have already — or will soon — come available for the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

Low-dose DES in the management of CRPC

Posted on August 19, 2011 by Sitemaster

The value of low-dose diethylstilbestrol (DES) in the management of men with advanced and castration-resistant prostate cancer (CRPC) comes up as a regular topic for review and discussion. Before development of the LHRH agonists, DES was the most commonly used — and much studied — drug for the treatment of advanced (metastatic) prostate cancer. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 2 Comments »

Combining a TKI with bicalutamide in men with CRPC

Posted on August 15, 2011 by Sitemaster

We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , | Leave a Comment »

Impact of abiraterone prior to chemotherapy — maybe not 4 years, but …

Posted on June 2, 2011 by Sitemaster

A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 3 Comments »

Wishful thinking about abiraterone acetate in CRPC

Posted on April 30, 2011 by Sitemaster

An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 12 Comments »

Next Page »
Follow

Get every new post delivered to your Inbox.

Join 827 other followers